NR3C2 and heart failure: It is important to recognize the continued relevance of mineralocorticoid receptor antagonists (MRAs), which are well-established disease-modifying medical therapies that decrease cardiovascular mortality and reduce the risk of heart failure hospitalizations in patients with HFrEF.6, 7, 8 Nevertheless, several uncertainties remain regarding MRA-incorporated medical therapy.